Summary: In this issue, Infarinato and colleagues report the results of preclinical testing of a novel ALK/ROS1 inhibitor, PF-06463922, in neuroblastoma. This small-molecule inhibitor was shown to efficiently inhibit the growth of patient-derived and established neuroblastoma xenograft models expressing mutated ALK. Although the in vivo data are impressive and the authors suggest that clinical trials are warranted, the presented data also suggest that it is as yet too early to welcome the new drug as a magic bullet. Cancer Discov; 6(1); 20–1. ©2016 AACR.
See related article by Infarinato et al., p. 96.
from Cancer via ola Kala on Inoreader http://ift.tt/1ZRepwu
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου